NASDAQ:ZSAN Zosano Pharma (ZSAN) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free ZSAN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range$0.52▼$112.0052-Week Range$0.46▼$37.45Volume5,685 shsAverage Volume425,375 shsMarket Capitalization$980.40P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zosano Pharma alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Zosano Pharma Stock (NASDAQ:ZSAN)Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! ZSAN Stock News HeadlinesApril 12, 2024 | seekingalpha.comHOOK HOOKIPA Pharma Inc.May 18, 2023 | bizjournals.comEast Bay Business NewsApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 6, 2023 | forbes.comAstellas PharmaFebruary 5, 2023 | finance.yahoo.comGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationNovember 5, 2022 | ca.finance.yahoo.comZosano Pharma Corporation (ZSANQ)October 12, 2022 | msn.comBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma GiantsAugust 28, 2022 | marketwatch.comBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of ClaimsApril 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...August 27, 2022 | bizjournals.comEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionAugust 25, 2022 | investing.comZosano Pharma Corp (ZSANQ)July 26, 2022 | bizjournals.comEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1MJuly 26, 2022 | bizjournals.comA Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.June 2, 2022 | marketwatch.comZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANJune 2, 2022 | msn.comWhy Zosano Pharma Shares Are Getting Hammered TodayJune 2, 2022 | seekingalpha.comZosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%June 2, 2022 | marketwatch.comCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANJune 2, 2022 | bizjournals.comEast Bay migraine patch developer files for bankruptcyJune 2, 2022 | finance.yahoo.comZosano Pharma Files Voluntary Petition for Relief Under Chapter 11May 18, 2022 | apnews.comEmergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle PatchMay 13, 2022 | investing.comZosano Pharma Reports Q1 Net Loss of $33.4MMay 13, 2022 | finance.yahoo.comZosano Pharma Reports First Quarter 2022 Financial ResultsMay 3, 2022 | finance.yahoo.comZosano Pharma Corporation (ZSAN) Outpaces Stock Market Gains: What You Should KnowApril 29, 2022 | bizjournals.comMigraine patch Zosano Pharma developer suspends program, cutting more jobsApril 29, 2022 | finance.yahoo.comMigraine patch developer Zosano Pharma suspends program, cutting more jobsApril 29, 2022 | seekingalpha.comZosano Pharma suspends program for migraine treatment M207April 29, 2022 | finance.yahoo.comZosano Pharma Provides Corporate UpdateSee More Headlines Receive ZSAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zosano Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2022Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZSAN CUSIPN/A CIK1587221 Webwww.zosanopharma.com Phone(510) 745-1200FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($14.5034) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,920,000.00 Net Margins-8,375.11% Pretax Margin-8,375.11% Return on Equity-177.06% Return on Assets-119.14% Debt Debt-to-Equity RatioN/A Current Ratio1.61 Quick Ratio1.61 Sales & Book Value Annual Sales$790,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.74 per share Price / Book0.00Miscellaneous Outstanding Shares4,902,000Free Float4,784,000Market Cap$980.40 OptionableNot Optionable Beta3.30 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Steven Lo (Age 55)Sr. VP of Operations, Pres, CEO & Director Comp: $534.08kMs. Christine Matthews (Age 53)Chief Financial Officer Comp: $312.45kDr. Donald J. Kellerman (Age 67)VP of Clinical Devel. & Medical Affairs Comp: $376.17kMs. Lu LiuVP of Technical OperationsJeffrey L. QuillenSec.Ms. Kristina WargaVP & Corp. ControllerMore ExecutivesKey CompetitorsOncoSec MedicalNASDAQ:ONCSQViveve MedicalNASDAQ:VIVEHTG Molecular DiagnosticsNASDAQ:HTGMQKaleido BiosciencesNASDAQ:KLDOContext TherapeuticsNASDAQ:CNTXView All Competitors ZSAN Stock Analysis - Frequently Asked Questions How were Zosano Pharma's earnings last quarter? Zosano Pharma Co. (NASDAQ:ZSAN) issued its quarterly earnings results on Friday, May, 13th. The biotechnology company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($1.75) by $0.01. Zosano Pharma had a negative net margin of 8,375.11% and a negative trailing twelve-month return on equity of 177.06%. When did Zosano Pharma's stock split? Zosano Pharma's stock reverse split on Tuesday, April 12th 2022. The 1-35 reverse split was announced on Tuesday, April 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Zosano Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Aeterna Zentaris (AEZS), Pennsylvania Real Estate Investment Trust (PEI), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Hallador Energy (HNRG) and EnLink Midstream (ENLC). When did Zosano Pharma IPO? Zosano Pharma (ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. This page (NASDAQ:ZSAN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zosano Pharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
